Javascript must be enabled to continue!
Abstract P174: Incidence of Hyponatremia on Spironolactone in Patients With a Prior Episode of Chlorthalidone-Induce Hyponatremia
View through CrossRef
Chlorthalidone and spironolactone are commonly used diuretics for patients with difficult-to-manage hypertension. Hyponatremia is a common adverse effect that results in discontinuing these medications in many subjects. We designed this study to determine the incidence of hyponatremia on spironolactone after developing a hyponatremic episode on chlorthalidone. Electronic health records were searched for patients seen at UAB’s outpatient clinics. Inclusion criteria included: patients who developed hyponatremia (serum sodium <133 mEq/L) on chlorthalidone within 90 days of starting the medication and had a prescription for spironolactone at another time point. The sodium levels were checked for 90 days after starting spironolactone. Exclusion criteria constituted having one of the following: heart failure, liver cirrhosis or adrenal insufficiency based on ICD 10 codes or an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73 m2. Preliminary analysis yielded eligible 14 patients. Eight had hyponatremia on chlorthalidone, but tolerated spironolactone well, and 6 had hyponatremia on both diuretics. Females comprised 13 out of 14 (92.9%) of the population. There were no significant differences in age, gender, race, baseline sodium level, sodium level at the hyponatremic episode or eGFR between the two groups. These findings suggest that checking sodium levels frequently for those who had hyponatremia with chlorthalidone and are prescribed subsequently spironolactone is warranted.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract P174: Incidence of Hyponatremia on Spironolactone in Patients With a Prior Episode of Chlorthalidone-Induce Hyponatremia
Description:
Chlorthalidone and spironolactone are commonly used diuretics for patients with difficult-to-manage hypertension.
Hyponatremia is a common adverse effect that results in discontinuing these medications in many subjects.
We designed this study to determine the incidence of hyponatremia on spironolactone after developing a hyponatremic episode on chlorthalidone.
Electronic health records were searched for patients seen at UAB’s outpatient clinics.
Inclusion criteria included: patients who developed hyponatremia (serum sodium <133 mEq/L) on chlorthalidone within 90 days of starting the medication and had a prescription for spironolactone at another time point.
The sodium levels were checked for 90 days after starting spironolactone.
Exclusion criteria constituted having one of the following: heart failure, liver cirrhosis or adrenal insufficiency based on ICD 10 codes or an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.
73 m2.
Preliminary analysis yielded eligible 14 patients.
Eight had hyponatremia on chlorthalidone, but tolerated spironolactone well, and 6 had hyponatremia on both diuretics.
Females comprised 13 out of 14 (92.
9%) of the population.
There were no significant differences in age, gender, race, baseline sodium level, sodium level at the hyponatremic episode or eGFR between the two groups.
These findings suggest that checking sodium levels frequently for those who had hyponatremia with chlorthalidone and are prescribed subsequently spironolactone is warranted.
Related Results
(034) Spironolactone and Sexual Dysfunction in Premenopausal Acne Patients: A TriNetX Database Analysis
(034) Spironolactone and Sexual Dysfunction in Premenopausal Acne Patients: A TriNetX Database Analysis
Abstract
Introduction
Spironolactone is a mineralocorticoid receptor antagonist commonly prescribed for off-label therapy...
PMON47 Fluid restriction reduces hyponatremia and hospital readmission rates following pituitary surgery
PMON47 Fluid restriction reduces hyponatremia and hospital readmission rates following pituitary surgery
Abstract
Rationale: Hyponatremia occurs in approximately 20% of patients after transsphenoidal pituitary surgery (TSS). Sympto...
Développement et évaluation de nouvelles formulations oculaires de spironolactone pour les segments antérieur et postérieur de l'œil
Développement et évaluation de nouvelles formulations oculaires de spironolactone pour les segments antérieur et postérieur de l'œil
Les glucocorticoïdes (GCs) sont les molécules les plus utilisées en ophtalmologie pour leurs effets anti-inflammatoires, anti-angiogéniques et anti-oedémateux. Ils se lient au réce...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract P187: Incidence and Predictors of Diuretic-Induced Hyponatremia
Abstract P187: Incidence and Predictors of Diuretic-Induced Hyponatremia
Hyponatremia is a common adverse effect of diuretic use. The purpose of this study was to determine the incidence of Diuretic-induced hyponatremia (DIH) (serum sodium <133mEq/L)...
7050 Effect of Spironolactone On Reducing Sugar-Induced Cellular Damage In MC3T3-E1 Osteoblastic Cells
7050 Effect of Spironolactone On Reducing Sugar-Induced Cellular Damage In MC3T3-E1 Osteoblastic Cells
Abstract
Disclosure: S. Yun: None. H. Sang: None. S. Park: None. K. Suh: None. H. Kim: None. S. Chin: None.
Background: In diabetes, prolonged hypergl...
Wild-type transthyretin amyloid cardiomyopathy: spironolactone as a therapeutic option?
Wild-type transthyretin amyloid cardiomyopathy: spironolactone as a therapeutic option?
Abstract
Introduction
Wild-type transthyretin cardiac amyloidosis (wtATTR-CM) is increasingly recognized as an important ...
Cost Issues in Hyponatremia
Cost Issues in Hyponatremia
Purpose
To describe the morbidity and mortality associated with hyponatremia and its impact on health care costs and outcomes in the United States, describe the...

